Pancreatic ductal adenocarcinoma (PDAC) · None

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Track	standard
Linked regimen	`None`

ID	`IND-CHRONIC-PANCREATITIS-PDAC-PREVENTION-SURVEILLANCE`
Type	Indication
Status	reviewed 2026-05-18 \| pending_clinical_signoff
Diseases	`DIS-PDAC`
Sources	`SRC-NCCN-BCELL-2025`

Notes

STUB — v0.3 chronic-condition pilot (chronic pancreatitis). Two-Co-Lead signoff queued.

Used By

Actionability

BMA-CA-19-9-PANCREATIC-CAPS-SURVEILLANCE - CA 19-9 is the principal serum biomarker for pancreatic ductal adenocarcinoma (PDAC) — us...